Santhera Pharmaceuticals Software Purchases and Digital Transformation Initiatives

Discover the latest software purchases and digital transformation initiatives being undertaken by Santhera Pharmaceuticals and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 106 Santhera Pharmaceuticals employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Santhera Pharmaceuticals has purchased the following applications: Veeva CRM for CRM in 2017, Cvent Event Management for Event Management in 2017, Hetzner for Application Hosting and Computing Services in 2018 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Santhera Pharmaceuticals is running and its propensity to invest more and deepen its relationship with Veeva Systems , Cvent , Hetzner or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Santhera Pharmaceuticals revenues, which have grown to $23.0 million in 2023, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Santhera Pharmaceuticals intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.

About the Customer

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs.

Santhera Pharmaceuticals is focusing on the development of treatments for neuro-ophthalmological, neuromuscular and pulmonary diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and cystic fibrosis (CF).

Scope and Challenges

On June 28, 2017 — Veeva Systems announced that Santhera Pharmaceuticals selected Veeva CRM and Veeva OpenData as a commercial software and data platform for its first product launch. The rare disease pharmaceutical company is adopting Veeva Commercial Cloud solutions to establish a consistent, global approach to commercialization.

A recent survey showed that the majority of companies struggle with customer data quality issues. Incorrect physician addresses, not knowing which doctors to contact, or outdated information about specialty and license status create frustration among field teams and impact efficiency. Bad data can also lead to compliance risks.

Outcome and Implications

Accurate customer data is foundational for commercial excellence, especially with today’s growing number of stakeholders. Veeva brings together complete customer data and multichannel engagement to help life sciences organizations enhance their interactions with healthcare professionals worldwide.

Field teams have up-to-date customer reference data where they need it most to enable faster and tailored interactions. When users submit data change requests, they are properly verified and updated in hours versus the industry average of 10 or more days.

Quotes

“There is a major transition happening across the industry as companies focus on better customer data for improved commercial effectiveness. Veeva OpenData and Veeva CRM are changing how the life sciences industry sources and manages data to drive greater speed, productivity, and execution globally, ” said Guillaume Roussel, director of strategy for Veeva OpenData.